Perform Medical Launches Comprehensive Hormone Balancing Program for Men and Women in the Greater Charleston Area
SUMMERVILLE, SC, UNITED STATES, June 17, 2025 / EINPresswire.com / -- Perform Medical, a premier wellness clinic serving the Lowcountry, proudly announces the launch of its advanced, personalized hormone balancing programs for both men and women. Under the clinical leadership of Taylor Vaughan, Medical Director, MBA, and Kaley Morris, Physician Assistant, the initiative offers an integrative, results-driven approach to correcting hormonal imbalances that impact health, vitality, and quality of life.
At Perform Medical, the mission is clear: Reclaim Your Health, Hormone by Hormone. With the understanding that hormone shifts are a natural part of aging, the clinic empowers patients to stop merely enduring the symptoms and instead regain their energy, clarity, and confidence through customized hormone therapy.
Why Hormone Balance Matters
Hormones govern nearly every system in the human body—from metabolism and mood to sexual health and mental clarity. When these powerful messengers fall out of sync, patients may experience symptoms such as:
- Chronic fatigue and poor sleep
- Weight gain and muscle loss
- Mood swings, anxiety, and depression
- Low libido and sexual dysfunction
- Brain fog and poor concentration
- Hot flashes and night sweats
Whether the imbalance stems from aging, menopause, andropause, or chronic stress, Perform Medical's team addresses the root causes with medical precision and compassionate care.
Tailored Care for Men
Men facing symptoms of low testosterone—such as reduced motivation, decreased muscle mass, erectile dysfunction, and mental fog—can benefit from Perform Medical's Testosterone Replacement Therapy (TRT). The clinic offers multiple delivery options, including bio-identical hormone pellets, injections, and fertility-preserving alternatives like Clomiphene or Enclomiphene.
Each program begins with advanced hormone panel testing and includes ongoing lab monitoring to ensure optimal, long-lasting results. Estrogen blockers are also available to help manage potential side effects, ensuring that each plan is customized to the individual's goals and lifestyle.
Empowering Women Through Every Life Stage
For women navigating perimenopause, menopause, or postmenopause, Perform Medical delivers cutting-edge bio-identical hormone replacement therapy (BHRT) to alleviate hot flashes, mood instability, low libido, and more. Led by Kaley Morris, PA-C, the women's program includes pellet therapy, topical hormone creams, and integrated wellness support to restore balance naturally and effectively.
The clinic's BHRT pellets—plant-based and structurally identical to human hormones—offer long-term, steady-release dosing without the daily hassle of pills or creams. They are a preferred option for women seeking consistent relief and convenience.
The Perform Medical Difference
Perform Medical stands out for its deep specialization in hormonal health, evidenced by:
- Expert Clinicians: Board-certified providers with advanced training in hormone therapy
- Individualized Care Plans: No cookie-cutter protocols—just precision medicine based on lab data and symptoms
- Local Support: A patient-first approach rooted in the Charleston community
- Whole-Body Wellness: Hormone therapy integrated with sexual wellness, medical weight loss, and functional health programs
Now Serving the Greater Charleston Area
Perform Medical is currently welcoming patients from Summerville, Charleston, Mount Pleasant, Daniel Island, Isle of Palms, Sullivans Island, Kiawah Island, Moncks Corner, Goose Creek, and North Charleston.
Is Hormone Therapy Right for You?
If you've asked yourself questions like:
- 'Why am I tired all the time?'
- 'Is there a better way to handle menopause?'
- 'What can I do about brain fog and low libido?'
- 'Where can I get testosterone therapy in Charleston?'
…it may be time to explore your hormonal health.
To learn more or schedule their personalized hormone consultation, individuals can contact Perform Medical today at (843) 278-8474.
About Perform Medical
Perform Medical is a functional wellness clinic based in Charleston, SC, specializing in hormone health, sexual wellness, regenerative medicine, and medical weight loss. Led by Dr. Taylor Vaughan and Kaley Morris, PA-C, the clinic is dedicated to restoring health through advanced diagnostics, evidence-based therapies, and compassionate care.
Taylor Vaughan, MD, MBA
Perform Medical
+1 843-278-8474
email us here
Visit us on social media:
Instagram
Facebook
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
PODD Drug Delivery Conference Announces 2025 Keynotes
The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 keynotes NEW YORK, June 18, 2025 /PRNewswire/ -- Today, PODD: Partnership Opportunities in Drug Delivery conference announced the keynotes for its 15th annual conference which takes place on October 27-28 at the Westin Copley Place in Boston, MA. "In presenting a strategic-level program for R&D scientists and business development professionals, the PODD Conference is committed to securing keynotes who demonstrate excellence in science," said Andrew Goldstein, Senior Conference Producer for the PODD Conference. The PODD 2025 keynotes include: MIT's Dr Robert Langer, a pioneer in the research and development of drug delivery technology, will return as the Annual Keynote to discuss the state of innovation in the drug delivery industry. Dr Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor who drove the development of GLP-1 drugs for obesity will present on the liraglutide and semaglutide story, her approach to scientific development and where drug delivery intersects with her R&D work. Patient Keynote Jimi Olaghere will share his journey as a patient with sickle cell disease before and after receiving CASGEVY, a CRISPR-based therapy, and his mission to make these therapies more accessible for patients globally. Dr Mansoor Amiji, University Distinguished Professor, Northwestern University, will join the PODD Conference as the Endogenous Delivery Zeitgeist. Dr Amiji will present on endogenous targeted delivery strategies to overcome biological barriers and improve efficacy and safety. The PODD speaking faculty includes over 100 executives from both the drug development and delivery industries with over 125 session choices including a full afternoon of drug delivery presentations from established to start-up companies. To learn more about the event, visit About the PODD: Partnership Opportunities in Drug Delivery ConferencePharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals, and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptides, oligonucleotides, biologics, small molecules and more. PODD provides business development opportunities through organized networking and a partnering tool for new, emerging and established collaborations. About the Conference ForumThe Conference Forum is a life science industry research firm that develops conferences, podcasts, newsletters and webinars primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, promoting the exchange of ideas and solutions among peers, and providing high-quality networking. Learn more about the Conference Forum at For media inquiries, contact:Bre Bugbee-Barrettbre@ View original content: SOURCE Partnership Opportunities in Drug Delivery (PODD)
Associated Press
an hour ago
- Associated Press
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
NORTH CHICAGO, Ill., June 18, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA® / AQUIPTA®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.1 The study met the primary endpoint of treatment discontinuation due to adverse events (AEs), demonstrating that atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, had fewer discontinuations due to AEs than topiramate, an anticonvulsant medication also approved for migraine prevention. Over the 24-week double-blind treatment period, discontinuation due to AEs was significantly lower with atogepant (12.1%) compared to topiramate (29.6%), representing a relative risk of 0.41 (95% CI: 0.28, 0.59; p<0.0001).1 The study also met all six secondary endpoints, including a key measure of clinical efficacy: 64.1% of patients on atogepant achieved a ≥50% reduction in mean monthly migraine days (MMD) during months 4 to 6 of the double-blind treatment period compared to 39.3% of patients on topiramate (p<0.0001).1 'These TEMPLE data affirm recommendations from the American Headache Society and International Headache Society, highlighting the role of CGRP pathway inhibitors as first-line preventive treatment options for migraine,' said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. 'This study demonstrates our commitment to improving treatment options and advancing care standards for people living with this debilitating disease.' Migraine continues to be underdiagnosed and undertreated, despite significant burden on patients' lives.2 It is a complex neurological disease that affects approximately 14% of the global population and ranks as the second leading cause of disability worldwide.2 Despite its prevalence and disabling impact, there are numerous gaps in patient care related to the standards for preventive treatment. Notably, over 50% of people currently using preventive medications still qualify for further preventive treatment, indicating that their current therapies may not be providing sufficient relief.3 'Far too often, people living with migraine struggle with meeting their treatment goals despite available and accessible preventive options,' said Jaclyn Duvall, M.D., neurologist and founder of Headache Specialists of Oklahoma. 'The TEMPLE data provide a patient-centered measure of treatment effectiveness by capturing both efficacy and tolerability, representing a meaningful way to evaluate the real-world impact of treatment persistence in migraine prevention.' The AE profile of atogepant observed in this active-controlled study was generally consistent with its established safety profile from prior studies.1 Atogepant, marketed as AQUIPTA® in the EU and QULIPTA® in the U.S., Canada, Israel and Puerto Rico, is approved in 60 countries. Atogepant is a once-daily oral CGRP receptor antagonist, proven to prevent both episodic and chronic migraine in adults. Full results from the TEMPLE study will be presented at an upcoming medical meeting. About the TEMPLE Study TEMPLE is a Phase 3, multicenter, randomized, double-blind, active-controlled trial evaluating the tolerability, safety, and efficacy of atogepant versus topiramate in adult patients with a history of four or more migraine days per month. The trial randomized 545 participants with episodic or chronic migraine aged 18 and older across 73 sites in Europe, Israel and Canada. The study was conducted in two distinct periods. In the initial 24-week Double-Blind Treatment Period, which included a 6-week up-titration phase and an 18-week maintenance phase, participants were randomized to receive either atogepant (60 mg once daily) or the highest tolerated dose of topiramate (ranging from 50 to 100 mg/day). Following this, eligible participants continued into a 52-week Open-Label Treatment Period, during which all received atogepant (60 mg once daily). Throughout the study, patient reported outcomes were regularly collected and patients were continuously monitored for safety and tolerability through clinical assessments and lab tests. The primary endpoint was the percentage of patients who discontinued the study treatment due to AEs during the 24-week double-blind treatment period. An electronic diary (eDiary) was used to collect data on headache frequency, duration, symptoms, acute medication use, and various patient-reported outcomes. More information on the TEMPLE trial can be found on (NCT05748483). About Atogepant Atogepant is a once-daily orally administered CGRP receptor antagonist specifically developed for the preventive treatment of migraine in adults. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks. Atogepant, marketed as AQUIPTA® in the EU and QULIPTA® in the U.S., Canada, Israel and Puerto Rico, is approved in 60 countries. U.S. Uses and Important Safety Information What is QULIPTA® (atogepant)? QULIPTA is a prescription medicine used for the preventive treatment of migraine in adults. IMPORTANT SAFETY INFORMATION FOR QULIPTA® Do not take QULIPTA if you have had an allergic reaction to atogepant or any ingredients in QULIPTA. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines. QULIPTA can cause serious side effects, including: The most common side effects of QULIPTA are nausea, constipation, and fatigue/sleepiness. These are not all the possible side effects of QULIPTA. QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit to learn more. Please see full Prescribing Information. Globally, prescribing information varies; refer to the individual country product label for complete information. About AbbVie in Migraine At AbbVie, we are committed to empowering people living with migraine disease. We advance science that enables healthcare providers to care for people impacted across the spectrum of migraine. Through education and partnerships with the migraine community, we strive to help those with migraine navigate barriers to care, access effective treatments, and reduce the impact of migraine on their lives. In the United States, AbbVie is the only company with three prescription treatments designed to meet patient needs across the spectrum of migraine to help patients living with this debilitating disease. About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. ALL-NEUR-250043 Contact(s): Global Media: Amber Landis +1 (231) 557-6596 [email protected] U.S. Media: Sara Sanders +1 (973) 307-6145 [email protected] References View original content: SOURCE AbbVie
Associated Press
an hour ago
- Associated Press
ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain
BALTIMORE--(BUSINESS WIRE)--Jun 18, 2025-- ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced it has treated the first patient in its HYDRAFIL-D FDA investigational device exemption (IDE) clinical trial for its HYDRAFIL ® System for disc augmentation. The patient was enrolled by Kas Amirdelfan, M.D., an interventional pain physician and founding member of Boomerang Healthcare, Inc. in Walnut Creek, Calif. The HYDRAFIL System is an outpatient procedure offering interventional pain physicians and patients a new treatment designed to reduce pain and improve daily function without the need for an invasive surgery. The launch of the HYDRAFIL-D U.S. study follows the company's receipt of CE Mark for the HYDRAFIL System based on promising results of clinical studies performed outside the United States on 75 patients. The studies showed that patients treated with HYDRAFIL experienced clinically and statistically significant improvements in pain and disability, with more than 80% improvement in Oswestry Disability Index (ODI) scores and greater than 70% reduction in Numeric Pain Rating Scale scores, with reductions sustained for two years in the 63 patients that have completed their two-year follow-up visit. 'An overwhelming majority of my chronic low back pain patients either do not want or are not good candidates for invasive spine surgeries, yet they continue to feel debilitated, without many treatment options,' said Dr. Amirdelfan. 'The early data on HYDRAFIL is compelling and promising for our subjects. I am excited to be working with ReGelTec and the other principal investigators to enroll the HYDRAFIL-D Study and evaluate the impact of HYDRAFIL on patients with degenerative disc disease.' The HYDRAFIL-D study is a 225-patient, multicenter, single-blinded, randomized, controlled trial evaluating the safety and effectiveness of the HYDRAFIL System to support FDA approval. The study will measure improvements in pain and disability, reliance on opioid medications, and the need for invasive medical procedures in patients with chronic low back pain due to degenerative disc disease. The protocol includes an interim safety analysis when the first sixty patients complete their six-month follow-up visit. There are nine study sites currently enrolling patients in Birmingham, Ala.; Walnut Creek, Calif.; Greenwood Village, Colo.; Jasper, Ga.; Shreveport, La.; Edmond, Okla.; Tyler, Texas; Richmond, Virginia; and Calgary, Canada, with additional sites being added. More than one in 10 U.S. adults suffer from chronic low back pain. 1 About 42% of this population, or more than 10 million Americans, has degenerative disc disease 2, a condition that is the largest contributor to chronic low back pain where intervertebral discs in the spine deteriorate and lose their height and volume. Degenerating discs cause vertebrae to move abnormally and inflame surrounding spinal structures, muscles, joints and nerves, resulting in pain in the back and sometimes the leg. Performed in an outpatient procedure under local anesthesia, ReGelTec's HYDRAFIL System delivers a permanent hydrogel into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. When the hydrogel implant solidifies in the disc, it distributes the load and strain felt in that intervertebral segment to improve function and reduce the pain signaling to the brain. 'I have been working with doctors and scientists for more than twenty years to develop a treatment for chronic low back pain, and in HYDRAFIL, we believe we've built a low-risk, effective option to fill a major market need,' said Tony Lowman, the inventor of HYDRAFIL and founder of ReGelTec. 'We look forward to fully enrolling the trial and securing FDA approval for the HYDRAFIL System so that patients in the United States with degenerative disc disease can benefit from this innovative, minimally invasive treatment option.' Patients interested in learning more about the HYDRAFIL-D Study can visit ABOUT REGELTEC, INC. ReGelTec is a clinical-stage privately held biomedical company dedicated to developing and commercializing a percutaneous hydrogel implant for the treatment of chronic low back pain due to degenerative disc disease. ReGelTec's HYDRAFIL System is an outpatient disc augmentation procedure where a permanent hydrogel is delivered into a degenerated disc via a needle to fill cracks and fissures and recruit water into the disc to restore natural biomechanics and provide pain relief. For more information, please visit 1 Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-1694. doi: 10.1002/acr.22890. PMID: 26991822; PMCID: PMC5027174. 2 Michael J. DePalma, Jessica M. Ketchum, Thomas Saullo, What Is the Source of Chronic Low Back Pain and Does Age Play a Role?, Pain Medicine, Volume 12, Issue 2, February 2011, Pages 224–233, View source version on CONTACT: MEDIA CONTACT: Sam Choinski Pazanga Health Communications (860) 301-5058 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MARYLAND INDUSTRY KEYWORD: RESEARCH SURGERY MEDICAL DEVICES FDA HOSPITALS CLINICAL TRIALS HEALTH TECHNOLOGY HEALTH SCIENCE SOURCE: ReGelTec Inc. Copyright Business Wire 2025. PUB: 06/18/2025 07:05 AM/DISC: 06/18/2025 07:04 AM
